Shares of Geron Co. (NASDAQ:GERN) have earned a consensus rating of “Buy” from the nine brokerages that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $3.55.
A number of research firms have weighed in on GERN. BidaskClub raised Geron from a “sell” rating to a “hold” rating in a research note on Saturday, August 17th. ValuEngine upgraded Geron from a “hold” rating to a “buy” rating in a report on Saturday, August 10th. B. Riley raised their target price on Geron from $3.25 to $4.50 and gave the stock a “buy” rating in a research note on Friday, June 28th. HC Wainwright started coverage on Geron in a report on Tuesday, September 3rd. They set a “buy” rating and a $4.00 price target on the stock. Finally, Cantor Fitzgerald started coverage on shares of Geron in a research report on Thursday, August 15th. They set an “overweight” rating and a $4.00 price target on the stock.
Hedge funds have recently added to or reduced their stakes in the company. Deutsche Bank AG raised its holdings in Geron by 155.0% in the 4th quarter. Deutsche Bank AG now owns 887,681 shares of the biopharmaceutical company’s stock valued at $887,000 after buying an additional 539,621 shares during the period. BNP Paribas Arbitrage SA lifted its holdings in shares of Geron by 6,429.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 36,629 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 36,068 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Geron by 667.9% in the 1st quarter. SG Americas Securities LLC now owns 433,705 shares of the biopharmaceutical company’s stock worth $720,000 after acquiring an additional 377,226 shares during the last quarter. Bienville Capital Management LLC purchased a new position in shares of Geron during the 1st quarter worth approximately $332,000. Finally, MetLife Investment Advisors LLC purchased a new position in shares of Geron during the 1st quarter worth approximately $150,000. 31.16% of the stock is currently owned by hedge funds and other institutional investors.
Geron (NASDAQ:GERN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. Geron had a negative return on equity of 22.33% and a negative net margin of 5,328.80%. The business had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.20 million. On average, equities analysts expect that Geron will post -0.43 earnings per share for the current fiscal year.
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.
Recommended Story: What is required to own or exchange cryptocurrency?
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.